Eli Lilly Q2 2025 Earnings
๐ Eli Lilly Q2 2025 Earnings: Strong Growth with a Cautionary Note
๐️ Result Declared: August 7, 2025
Ticker: NYSE: LLY
Eli Lilly reported impressive second-quarter results for 2025, driven by soaring demand for its weight-loss and diabetes treatments. While financial performance exceeded Wall Street expectations, a clinical trial miss in its oral obesity drug tempered investor enthusiasm, causing a drop in share price.
๐ Q2 2025 vs Q2 2024: Year-on-Year Financial Comparison
| Metric | Q2 2025 | Q2 2024 | YoY Change |
|---|---|---|---|
| Revenue | $15.56 billion | $11.42 billion | +36% |
| Reported EPS | $6.29 | $3.28 | +92% |
| Non-GAAP EPS | $6.31 | $3.92 | +61% |
| Gross Margin (Non-GAAP) | 85.0% | 79.7% | +5.3% pts |
| Mounjaro Sales | ~$5.20 billion | ~$3.10 billion | +68% |
| Zepbound Sales | ~$3.38 billion | ~$1.24 billion | +172% |
| Free Cash Flow | $4.12 billion | $2.45 billion | +68% |
๐ Highlights
- Mounjaro and Zepbound continue to outperform expectations in the diabetes and weight-loss segments.
- Raised full-year guidance to $60–62 billion in revenue and $21.75–$23.00 in non-GAAP EPS.
- Orforglipron showed solid but slightly underwhelming results, triggering a stock price dip.
๐ง Key Insight
Despite stellar financial results, biotech valuations often hinge on drug development outcomes. Investors will closely monitor how Lilly responds to competitive pressures from Novo Nordisk and others in the GLP-1 space.
Disclaimer: This post is for informational purposes only and does not constitute investment advice.
Comments
Post a Comment